サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1420987

抗がん剤市場：世界の産業分析、規模、シェア、成長、動向、予測、2023年～2031年

Anticancer Drugs Market (Drug Type: Cytotoxic Drugs, Targeted Drugs, and Hormonal Drugs; and Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 226 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
抗がん剤市場：世界の産業分析、規模、シェア、成長、動向、予測、2023年～2031年
出版日: 2023年12月07日
発行: Transparency Market Research
ページ情報: 英文 226 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗がん剤市場- レポートの範囲

世界の抗がん剤市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界の抗がん剤市場の収益を提供し、2017年から2031年の期間、2023年を基準年、2031年を予測年とみなします。レポートは、2023年から2031年までの世界の抗がん剤市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、抗がん剤市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 1,402億米ドル
2031年の市場価値 3,031億米ドル
CAGR 9.1%

このレポートは、世界の抗がん剤市場の競合情勢を詳しく調査しています。世界の抗がん剤市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の抗がん剤市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2023～2031年

第5章 重要な洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主な合併と買収
  • COVID-19のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：医薬品タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：医薬品タイプ別、2023-2031
    • 細胞毒性薬
      • アルキル化剤
      • 代謝拮抗物質
      • その他
    • 標的薬物
      • モノクローナル抗体
      • チロシンキナーゼ阻害剤
      • その他
    • ホルモン剤
  • 市場魅力度分析：医薬品タイプ別

第7章 世界市場の分析と予測：治療タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：治療タイプ別、2023-2031
    • 化学療法
    • 標的療法
    • 免疫療法
    • その他
  • 市場魅力度分析：治療タイプ別

第8章 世界市場の分析と予測：がんタイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：がんタイプ別、2023-2031
    • 肺がん
    • 乳がん
    • 白血病
    • 大腸がん
    • その他
  • 市場魅力度分析：がんタイプ別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2023-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東およびアフリカ市場の分析と予測

第15章 競合情勢

  • 市場プレーヤー- 競争マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd
    • Eli Lilly and Company
    • Novartis AG
    • Pfizer Inc
    • Bayer AG
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Merck &Co., Inc
    • CELGENE CORPORATION
    • Amgen Inc
図表

List of Tables

  • Table 01: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 02: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 03: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 04: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Region, 2023-2031
  • Table 05: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country, 2023-2031
  • Table 06: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 07: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 08: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 09: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 10: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 11: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 12: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 13: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 15: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 16: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 17: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 18: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 19: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 20: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031
  • Table 21: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 22: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023-2031
  • Table 23: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023-2031
  • Table 24: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023-2031

List of Figures

  • Figure 01: Global Anticancer Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031
  • Figure 02: Global Anticancer Drugs Market Revenue (US$ Mn), by Drug Type, 2022
  • Figure 03: Global Anticancer Drugs Market Value Share, by Drug Type, 2022
  • Figure 04: Global Anticancer Drugs Market Revenue (US$ Mn), by Therapy Type, 2022
  • Figure 05: Global Anticancer Drugs Market Value Share, by Therapy Type, 2022
  • Figure 06: Global Anticancer Drugs Market Revenue (US$ Mn), by Cancer Type, 2022
  • Figure 07: Global Anticancer Drugs Market Value Share, by Cancer Type, 2022
  • Figure 08: Global Anticancer Drugs Market Value Share, by Region, 2022
  • Figure 09: Global Anticancer Drugs Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 11: Global Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 12: Global Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 13: Global Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 14: Global Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 15: Global Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 16: Global Anticancer Drugs Market Value Share Analysis, by Region, 2023 and 2031
  • Figure 17: Global Anticancer Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 19: North America Anticancer Drugs Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Anticancer Drugs Market Value Share Analysis, by Country, 2023 and 2031
  • Figure 21: North America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 22: North America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 23: North America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 24: North America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 25: North America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 26:North America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 27: Europe Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 28: Europe Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 30: Europe Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 31: Europe Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 32: Europe Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 33: Europe Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 34: Europe Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 35: Europe Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 36: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 37: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 39: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 40: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 41: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 42: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 43: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 44: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 45: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 46: Latin America Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 48: Latin America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 49: Latin America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 50: Latin America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 51: Latin America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 52: Latin America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 53: Latin America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
  • Figure 54: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 55: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 57: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
  • Figure 58: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
  • Figure 59: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
  • Figure 60: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 61: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 62: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
目次
Product Code: TMRGL12458

Anticancer Drugs Market - Scope of Report

TMR's report on the global anticancer drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global anticancer drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anticancer drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anticancer drugs market.

Market Snapshot
Market Value in 2023US$ 140.2 Bn
Market Value in 2031US$ 303.1 Bn
CAGR9.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anticancer drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anticancer drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anticancer drugs market.

The report delves into the competitive landscape of the global anticancer drugs market. Key players operating in the global anticancer drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anticancer drugs market profiled in this report.

Key Questions Answered in Global anticancer drugs Market Report:

  • What is the sales/revenue generated by anticancer drugs across all regions during the forecast period?
  • What are the opportunities in the global anticancer drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Anticancer Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global anticancer drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global anticancer drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anticancer drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticancer Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Anticancer Drugs Market Analysis and Forecast, 2023-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Anticancer Drugs Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2023-2031
    • 6.3.1. Cytotoxic Drugs
      • 6.3.1.1. Alkylating Agents
      • 6.3.1.2. Antimetabolites
      • 6.3.1.3. Others
    • 6.3.2. Targeted Drugs
      • 6.3.2.1. Monoclonal Antibodies
      • 6.3.2.2. Tyrosine Kinase Inhibitors
      • 6.3.2.3. Others
    • 6.3.3. Hormonal Drugs
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Anticancer Drugs Market Analysis and Forecast, by Therapy Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Therapy Type, 2023-2031
    • 7.3.1. Chemotherapy
    • 7.3.2. Targeted Therapy
    • 7.3.3. Immunotherapy
    • 7.3.4. Others
  • 7.4. Market Attractiveness Analysis, by Therapy Type

8. Global Anticancer Drugs Market Analysis and Forecast, by Cancer Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Cancer Type, 2023-2031
    • 8.3.1. Lung Cancer
    • 8.3.2. Breast Cancer
    • 8.3.3. Leukemia
    • 8.3.4. Colorectal Cancer
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis, by Therapy Type

9. Global Anticancer Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2023-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Anticancer Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Type, 2023-2031
    • 10.3.1. Cytotoxic Drugs
      • 10.3.1.1. Alkylating Agents
      • 10.3.1.2. Antimetabolites
      • 10.3.1.3. Others
    • 10.3.2. Targeted Drugs
      • 10.3.2.1. Monoclonal Antibodies
      • 10.3.2.2. Tyrosine Kinase Inhibitors
      • 10.3.2.3. Others
    • 10.3.3. Hormonal Drugs
  • 10.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 10.4.1. Chemotherapy
    • 10.4.2. Targeted Therapy
    • 10.4.3. Immunotherapy
    • 10.4.4. Others
  • 10.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 10.5.1. Lung Cancer
    • 10.5.2. Breast Cancer
    • 10.5.3. Leukemia
    • 10.5.4. Colorectal Cancer
    • 10.5.5. Others
  • 10.6. Market Value Forecast, by Country, 2023-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Type
    • 10.7.2. By Therapy Type
    • 10.7.3. By Cancer Type
    • 10.7.4. By Country

11. Europe Anticancer Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Type, 2023-2031
    • 11.3.1. Cytotoxic Drugs
      • 11.3.1.1. Alkylating Agents
      • 11.3.1.2. Antimetabolites
      • 11.3.1.3. Others
    • 11.3.2. Targeted Drugs
      • 11.3.2.1. Monoclonal Antibodies
      • 11.3.2.2. Tyrosine Kinase Inhibitors
      • 11.3.2.3. Others
    • 11.3.3. Hormonal Drugs
  • 11.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 11.4.1. Chemotherapy
    • 11.4.2. Targeted Therapy
    • 11.4.3. Immunotherapy
    • 11.4.4. Others
  • 11.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 11.5.1. Lung Cancer
    • 11.5.2. Breast Cancer
    • 11.5.3. Leukemia
    • 11.5.4. Colorectal Cancer
    • 11.5.5. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Therapy Type
    • 11.7.3. By Cancer Type
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Anticancer Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Type, 2023-2031
    • 12.3.1. Cytotoxic Drugs
      • 12.3.1.1. Alkylating Agents
      • 12.3.1.2. Antimetabolites
      • 12.3.1.3. Others
    • 12.3.2. Targeted Drugs
      • 12.3.2.1. Monoclonal Antibodies
      • 12.3.2.2. Tyrosine Kinase Inhibitors
      • 12.3.2.3. Others
    • 12.3.3. Hormonal Drugs
  • 12.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 12.4.1. Chemotherapy
    • 12.4.2. Targeted Therapy
    • 12.4.3. Immunotherapy
    • 12.4.4. Others
  • 12.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 12.5.1. Lung Cancer
    • 12.5.2. Breast Cancer
    • 12.5.3. Leukemia
    • 12.5.4. Colorectal Cancer
    • 12.5.5. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Therapy Type
    • 12.7.3. By Cancer Type
    • 12.7.4. By Country/Sub-region

13. Latin America Anticancer Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Type, 2023-2031
    • 13.3.1. Cytotoxic Drugs
      • 13.3.1.1. Alkylating Agents
      • 13.3.1.2. Antimetabolites
      • 13.3.1.3. Others
    • 13.3.2. Targeted Drugs
      • 13.3.2.1. Monoclonal Antibodies
      • 13.3.2.2. Tyrosine Kinase Inhibitors
      • 13.3.2.3. Others
    • 13.3.3. Hormonal Drugs
  • 13.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 13.4.1. Chemotherapy
    • 13.4.2. Targeted Therapy
    • 13.4.3. Immunotherapy
    • 13.4.4. Others
  • 13.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 13.5.1. Lung Cancer
    • 13.5.2. Breast Cancer
    • 13.5.3. Leukemia
    • 13.5.4. Colorectal Cancer
    • 13.5.5. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Therapy Type
    • 13.7.3. By Cancer Type
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Anticancer Drugs Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Type, 2023-2031
    • 14.3.1. Cytotoxic Drugs
      • 14.3.1.1. Alkylating Agents
      • 14.3.1.2. Antimetabolites
      • 14.3.1.3. Others
    • 14.3.2. Targeted Drugs
      • 14.3.2.1. Monoclonal Antibodies
      • 14.3.2.2. Tyrosine Kinase Inhibitors
      • 14.3.2.3. Others
    • 14.3.3. Hormonal Drugs
  • 14.4. Market Value Forecast, by Therapy Type, 2023-2031
    • 14.4.1. Chemotherapy
    • 14.4.2. Targeted Therapy
    • 14.4.3. Immunotherapy
    • 14.4.4. Others
  • 14.5. Market Value Forecast, by Cancer Type, 2023-2031
    • 14.5.1. Lung Cancer
    • 14.5.2. Breast Cancer
    • 14.5.3. Leukemia
    • 14.5.4. Colorectal Cancer
    • 14.5.5. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Therapy Type
    • 14.7.3. By Cancer Type
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. F. Hoffmann-La Roche Ltd
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Eli Lilly and Company
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Novartis AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Pfizer Inc
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Bayer AG
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. AstraZeneca
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Takeda Pharmaceutical Company Limited
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Merck & Co., Inc
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. CELGENE CORPORATION
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Amgen Inc
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview